# Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

> **NCT03393000** · PHASE3 · TERMINATED · sponsor: **Diffusion Pharmaceuticals Inc** · enrollment: 19 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Trans Sodium Crocetinate plus SOC
- **OTHER:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT03393000
- **Lead sponsor:** Diffusion Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-16
- **Primary completion:** 2020-11-06
- **Final completion:** 2020-11-06
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Business decision on behalf of the Sponsor.
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393000, "Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03393000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*